NewLink Genetics (NLNK) Misses Q3 EPS by 12c

NewLink Genetics (NASDAQ: NLNK) reported Q3 EPS of ($0.39), $0.12 worse than the analyst estimate of ($0.27).

“We are excited about the proposed merger with Lumos Pharma that we announced at the close of the third quarter and continue to advance the process required to close the transaction,” commented Brad Powers, General Counsel and member of NewLink’s Office of the CEO. “We believe this merger positions the company to improve therapeutic options for patients with pediatric growth hormone deficiency and other rare and neglected diseases, and to bring greater value to our shareholders.”

Eugene Kennedy, MD, Chief Medical Officer and member of NewLink’s Office of the CEO added, “We are also pleased by the FDA’s recent acceptance of the biologic licensing application for priority review of our partnered investigational Ebola vaccine, which we licensed to Merck in 2014. We are encouraged, as well, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine. We believe these actions demonstrate the urgency with which regulatory bodies are addressing this deadly disease in order to help the affected individuals and communities.”

For earnings history and earnings-related data on NewLink Genetics (NLNK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Fort Technology posts 49% revenue rise in first half of 2026
• Movano (MOVE) Misses Q2 EPS by 195c